Baseline characteristics

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      0

   2. group Id

      BG001

      value

      0

   3. group Id

      BG002

      value

      0

   units

   Participants

groups

1. description

   Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial. Biospecimen Collection: Undergo collection of blood samples Bone Marrow Aspirate: Undergo bone marrow aspirate Bone Marrow Biopsy: Undergo bone marrow biopsy Computed Tomography: Undergo CT scan Ixazomib Citrate: Given PO Lenalidomide: Given PO Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies

   id

   BG000

   title

   Arm A (Lenalidomide, Ixazomib Citrate)

2. description

   Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial. Biospecimen Collection: Undergo collection of blood samples Bone Marrow Aspirate: Undergo bone marrow aspirate Bone Marrow Biopsy: Undergo bone marrow biopsy Computed Tomography: Undergo CT scan Lenalidomide: Given PO Placebo Administration: Given PO Positron Emission Tomography: Undergo PET scan Quality-of-Life Assessment: Ancillary studies Questionnaire Administration: Ancillary studies

   id

   BG001

   title

   Arm B (Lenalidomide, Placebo)

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. title

   Age, Continuous

2. classes

   1. categories

      1. title

         Female

      2. title

         Male

   title

   Sex: Female, Male

3. classes

   1. categories

      1. title

         Hispanic or Latino

      2. title

         Not Hispanic or Latino

      3. title

         Unknown or Not Reported

   title

   Ethnicity (NIH/OMB)

4. classes

   1. categories

      1. title

         American Indian or Alaska Native

      2. title

         Asian

      3. title

         Native Hawaiian or Other Pacific Islander

      4. title

         Black or African American

      5. title

         White

      6. title

         More than one race

      7. title

         Unknown or Not Reported

   title

   Race (NIH/OMB)

population Description

Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice